Related Experiment Video
Updated: Jun 23, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
A comparison of plasma Tsukushi in adolescents with and without metabolic dysfunction-associated steatotic liver
Sydni A McNeese1, Sadie A Maltz1, Youngsil Kim1
1Division of Diabetes and Endocrinology, Department of Pediatrics, University of Oklahoma Health Campus, Oklahoma City, Oklahoma, USA.
Abstract:
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common liver disease in children and adolescents. Assessment of circulating biomarkers is needed to understand the underlying pathology, disease severity, and treatment options. The secreted hepatokine Tsukushi (TSK) is involved in lipid and carbohydrate metabolism. TSK is increased in adults with MASLD but has yet to be reported in adolescents. We hypothesized that plasma TSK is increased in adolescents with MASLD compared to peers without MASLD classified as obese (Ob) or normal weight (NW). We tested adolescents 10-20 years old with obesity and biopsy-confirmed MASLD (17F, 46 M), and controls without MASLD with either Ob (16F, 16 M) or NW (15F, 20 M). Fasting plasma TSK concentration was 27% higher (p < 0.05) in the MASLD group (median [interquartile range]: 188 [120, 418] ng/mL) than the NW group (148 [80, 241]), while the Ob group was intermediate (165 [84, 466]) and not different from the other two groups. TSK did not differ across histological grades of steatosis or fibrosis. Although TSK was increased in the MASLD group compared to NW controls, the lack of difference in TSK between the Ob and MASLD groups limits its value as a potential biomarker for MASLD.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

